for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fresenius SE & Co KGaA

FREG.DE

Latest Trade

42.45EUR

Change

-1.38(-3.14%)

Volume

969,808

Today's Range

42.37

 - 

43.86

52 Week Range

38.28

 - 

62.02

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
43.83
Open
43.86
Volume
969,808
3M AVG Volume
38.22
Today's High
43.86
Today's Low
42.37
52 Week High
62.02
52 Week Low
38.28
Shares Out (MIL)
556.84
Market Cap (MIL)
24,163.04
Forward P/E
13.04
Dividend (Yield %)
1.84

Next Event

Q3 2019 Fresenius SE & Co KGaA Earnings Release

Latest Developments

More

Fresenius Kabi - Announced Immediate Availability In United States Of Phenylephrine Hydrochloride Injection, Usp

Fresenius CEO Says Open For More Hospital M&A Activities In Spain

Fresenius raises 2019 outlook

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.

Industry

Healthcare Facilities

Contact Info

Else-Kroener-Str. 1

+49.6172.6080

https://www.fresenius.de/

Executive Leadership

Gerd Krick

Independent Chairman of the Supervisory Board

Stephan Sturm

Chairman of the Management Board, Chief Executive Officer

Michael Diekmann

Independent Deputy Chairman of the Supervisory Board

Niko Stumpfoegger

Independent Deputy Chairman of the Supervisory Board

Dieter Schenk

Deputy Chairman of the Supervisory Board and Lawyer and Tax Consultant

Key Stats

2.08 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

29.1K

2017

33.9K

2018

33.5K

2019(E)

35.3K
EPS (EUR)

2016

2.920

2017

3.250

2018

3.630

2019(E)

3.324
Price To Earnings (TTM)
12.99
Price To Sales (TTM)
0.70
Price To Book (MRQ)
1.52
Price To Cash Flow (TTM)
4.92
Total Debt To Equity (MRQ)
169.26
LT Debt To Equity (MRQ)
133.83
Return on Investment (TTM)
8.04
Return on Equity (TTM)
5.07

Latest News

Latest News

Fresenius drops possible sale of blood transfusion unit - spokesman

German health care group Fresenius has abandoned plans to sell its blood transfusion business, a spokesman said on Sunday, confirming a German media report.

Fresenius' Helios division acquires two hospitals in Colombia

German healthcare group Fresenius said on Tuesday its hospitals division Helios had acquired two hospitals in Colombia for 50 million euros ($55.72 million) as the group strengthens its presence outside of Europe.

UPDATE 4-Fresenius slides as weakness in dialysis unit offsets improved outlook

* Fresenius expects FY 4%-7% revenue growth at constant currency

Fresenius raises full-year outlook after Q2 meets expectations

German healthcare group Fresenius raised full-year revenue targets on Tuesday as its adjusted second-quarter sales came in a touch above analysts' expectations.

Fresenius says tighter EU rules could trigger antibiotic shortage

German drugmaker Fresenius warned that stricter production norms being considered by Europe's drug regulator could compound shortages of a life-saving antibiotic that is used by about 25 million patients globally each year.

Fresenius CEO: Don't see us making any large acquisitions this year

German healthcare group Fresenius probably will not make any large acquisitions this year, the group's chief executive officer said on Friday, adding that this was more likely from next year.

Fresenius talking to potential suitors about sale of blood transfusion business - sources

Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday.

Fresenius talking to potential suitors about sale of blood transfusion business - sources

Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday.

UPDATE 2-Fresenius makes solid start to year after turbulent 2018

* Confirms full-year guidance (Adds analysts, shares, details)

Fresenius makes solid start to Q1 after troubled 2018

Fresenius reported a quarter of solid sales and earnings growth on Thursday helped by its generic infusion drugs and dialysis units and signs of stabilisation at its troubled German hospital business.

Fresenius may not be ideal owner for some business activities: CEO

German healthcare group Fresenius is happy with its current portfolio but may consider selling some non-core business activities within its units, its chief executive told an association of business journalists on Wednesday evening.

Fresenius flags faster earnings growth from 2020 after investment

Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday.

Fresenius expects earnings to stagnate in 2019 as investments weigh

German healthcare group Fresenius said sales growth would slow and profit stagnate this year as investments to fix the performance at its German hospitals business and build up home dialysis take a toll.

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

Akorn Inc <AKRX.O> said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE <FREG.DE>.

UPDATE 2-Fresenius plunges as health firm warns investment to hit profit

* Shares plunge 18 percent, poised for biggest one-day drop (Adds analyst comment, loss in market value)

Fresenius cuts guidance, vows further dividend hikes

German healthcare group Fresenius cut its medium-term guidance late on Thursday hurt by lower profit expectations at its dialysis arm FMC and its clinics chain Helios but said that dividends will continue to grow.

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest...

Fresenius says working to fix performance at dialysis business, German hospitals

Germany's Fresenius said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month.

German stocks - Factors to watch on Oct. 19

The following are some of the factors that may move German stocks on Friday:

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

Germany's Fresenius SE <FREG.DE> won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc <AKRX.O>, sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up